Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) shares rose 10.9% during mid-day trading on Friday . The company traded as high as $2.60 and last traded at $2.55. Approximately 748,700 shares changed hands during mid-day trading, an increase of 117% from the average daily volume of 345,200 shares. The stock had previously closed at $2.30.

AST has been the topic of a number of research analyst reports. Zacks Investment Research lowered shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. HC Wainwright reiterated a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday, November 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $8.94.

The stock has a market cap of $132.67, a PE ratio of -3.77 and a beta of 1.30.

COPYRIGHT VIOLATION NOTICE: “Asterias Biotherapeutics (AST) Stock Price Up 10.9%” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/01/14/asterias-biotherapeutics-ast-stock-price-up-10-9.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.